DUBLIN--(BUSINESS WIRE)--The "Heart
Transplant Rejection - Pipeline Review, H1 2018" drug pipelines
has been added to ResearchAndMarkets.com's offering.
This latest Pharmaceutical and Healthcare disease pipeline guide
provides an overview of the Heart Transplant Rejection (Immunology)
The guide covers the descriptive pharmacological action of the
therapeutics, its complete research and development history and latest
news and press releases.
Heart Transplant Rejection (Immunology) pipeline guide helps in
identifying and tracking emerging players in the market and their
portfolios, enhances decision making capabilities and helps to create
effective counter strategies to gain competitive advantage.
Additionally, various dynamic tracking processes ensure that the most
recent developments are captured on a real time basis.
- The pipeline guide provides a snapshot of the global therapeutic
landscape of Heart Transplant Rejection (Immunology).
- The pipeline guide reviews pipeline therapeutics for Heart Transplant
Rejection (Immunology) by companies and universities/research
institutes based on information derived from company and
- The pipeline guide covers pipeline products based on several stages of
development ranging from pre-registration till discovery and
- The pipeline guide features descriptive drug profiles for the pipeline
products which comprise, product description, descriptive licensing
and collaboration details, R&D brief, MoA & other developmental
- The pipeline guide reviews key companies involved in Heart Transplant
Rejection (Immunology) therapeutics and enlists all their major and
- The pipeline guide evaluates Heart Transplant Rejection (Immunology)
therapeutics based on mechanism of action (MoA), drug target, route of
administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued
- The pipeline guide reviews latest news related to pipeline
therapeutics for Heart Transplant Rejection (Immunology)
- Astellas Pharma Inc.
- Heat Biologics Inc.
- Noxxon Pharma AG
- TxCell SA
For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/c7qdk6/heart_transplant?w=4